12 results about "Lymphatic metastasis" patented technology

The invention relates to the field of molecular diagnosis and tumor risk assessment, in particular to a marker combination and a kit for assessing the lymphatic metastasis risk of cervical cancer and application of the marker combination and the kit. The marker comprises a group of gene markers and a group of microbial markers, the gene markers comprise CARD9, MNX1AS2, MRAS, OLFML2A and RPS28, preferably, the gene markers further comprise at least one of CFL1P1 and GRASLND, and the microbial markers comprise microorganisms of the genus Dialister, the genus Catonella and the genus Campylobacter. The marker provided by the invention can be used for constructing an accurate risk assessment model, and can be used for developing a corresponding PCR (Polymerase Chain Reaction) kit, a mass spectrum or a chromatographic analysis system to realize metastasis risk prediction, curative effect assessment and new drug screening of cervical cancer patients.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The invention provides a biomarker for diagnosing lymphatic metastasis of cervical cancer and application of the biomarker, and belongs to the field of medical diagnosis. According to the invention, three biomarkers of resting sulfydryl oxidase 1, paraoxonase 1 and keratin 6A for diagnosing lymphatic metastasis of cervical cancer are obtained through multivariate statistical analysis, difference screening, random forest, ROC analysis and other biosignal analysis methods. Based on the biomarker provided by the invention, a kit and the like for diagnosing lymphatic metastasis of cervical cancer are constructed, and the kit and the like are used for accurately judging whether lymphatic metastasis occurs in cervical cancer patients or not.

The invention belongs to the technical field of natural medicines, and particularly relates to application of ligustrazine in preparation of medicines for promoting lymphatic neogenesis and in-vitro activation of a VEGFC / VEGFR3 signal channel. It is found for the first time that ligustrazine can remarkably enhance the proliferation and migration capacity of HLECs, the number of lymphatic vessels in an infarct marginal area can be increased after MI, inflammatory cell infiltration can be relieved, the content of VEGFC in serum can be increased, expression of lymphatic vessel neogenesis related protein and genes can be promoted, the heart function can be improved, and myocardial cell damage can be relieved. The invention also finds that ligustrazine can activate a VEGFC / VEGFR3 signal channel. The invention provides a new active ingredient for developing a lymphatic vessel regulator for promoting lymphatic vessel neogenesis, provides a new thought and method for cardiac tissue repair and function improvement after MI, and also provides a new modeling drug for constructing a lymphatic metastasis model by activating a VEGFC / VEGFR3 signal channel in vitro and evaluating the curative effect of the anti-lymphatic metastasis drug.

The present invention discloses polypeptides translated from circular RNA-circMYCBP2 and their application in regulating bladder cancer, belonging to the field of tumor molecular biology. Taking the ability of circular RNA to encode short peptides or proteins as an entry point, the present invention screened out circMYCBP2, which is highly expressed in tissues of bladder cancer patients with positive lymphoma metastasis, and verified that its translation can translate the sequence MYCBP2-227aa shown in SEQ ID NO.1. At the same time, it also confirmed the promotion effect of MYCBP2-227aa on bladder cancer lymphatic metastasis, thereby revealing the biological role of MYCBP2-227aa in bladder cancer lymphatic metastasis, and providing a theoretical basis and scientific basis for MYCBP2-227aa as an early diagnostic marker and new treatment target for bladder cancer lymphatic metastasis.

The present invention relates to the use of luteolin to enhance the sensitization of cisplatin in the preparation of a drug for the treatment of esophageal squamous cell carcinoma. The present invention finds that luteolin can block the progression of esophageal squamous cell carcinoma cells in multiple aspects, including apoptosis induction, growth inhibition, and invasion inhibition. Luteolin can also significantly enhance the ability of cisplatin to inhibit the lymphatic metastasis of esophageal squamous cell carcinoma cells in a mouse model, demonstrating a significant synergistic effect between the two.

The invention discloses an early gastric cancer lymphatic metastasis risk auxiliary inspection method based on collagen fiber morphological structure fusion characteristics. An extracellular matrix collagenous fiber image of a gastric tumor tissue is obtained in an unmarked second harmonic imaging mode, and automatic early gastric cancer lymphatic metastasis risk assessment can be realized by performing quantitative calculation and analysis of multivariate parameter characteristics on morphological structure characteristics of the collagenous fiber. According to the method, the morphological structure characteristics of the gastric tumor collagenous fibers can be intuitively displayed through a pixel-level morphological characterization method, and the information readability is enhanced. According to the method, the complementarity of the morphological structure characteristics of the collagenous fibers of the gastric tumor tissue is remarkably improved through multi-element parameter characteristic characterization, and the accuracy of lymphatic metastasis risk assessment is further improved. According to the method, an early gastric cancer lymphatic metastasis risk specificity index is formed based on the multi-element morphological characteristics of collagenous fibers, and a local focus area can be quantitatively and intuitively displayed.

This invention discloses the application of lncRNA MAGE-A10-encoded short peptide in regulating lymph node metastasis and targeted therapy in bladder cancer, belonging to the field of biomedical technology. This invention focuses on the coding ability of long non-coding RNAs, using high-throughput sequencing and bioinformatics algorithms to screen for lncRNA MAGE-A10, which is highly expressed in lymph node metastasis-positive bladder cancer tissues. The coding ability was verified by predicting open reading frames, constructing expression vectors, and synthesizing specific antibodies. The encoded short peptide MAGE-A10-44aa was positively correlated with lymph node metastasis in bladder cancer and poor patient prognosis, and also promoted lymphangiogenesis and lymph node metastasis in bladder cancer. This confirms the biological role of the MAGE-A10-44aa short peptide in bladder cancer lymph node metastasis, providing a potential target for bladder cancer treatment.

The invention discloses an FELDI nano-particle chip kit and application thereof in screening metabolic marker combinations, and relates to the technical field of biology. The FELDI nano-particle chip kit comprises a methanol solution and a microarray chip which is pre-coated with iron nano-particles, the kit is used for dewaxing tissue slices, the tissue slices are immersed in a methanol solution and incubated to obtain a sample, and the sample is applied to a microarray chip pre-coated with iron nanoparticles; a colorectal cancer tissue metabolism fingerprint database is constructed, and specific metabolism markers combined with L-cysteine, adipic acid, decanoic acid, azelaic acid, pentadecanoic acid, stearic acid and isolithocholic acid are screened. The invention develops an unmarked iron nanoparticle enhanced laser desorption ionization mass spectrometry technology platform, and the small molecule metabolites can be directly and efficiently captured and ionized from the formalin-fixed paraffin-embedded CRC primary tissue section. And screening out a specific small molecule metabolism marker combination for distinguishing lymphatic metastasis and non-metastasis.

The present invention discloses the role of SEMA-123aa, encoded by circSEMA3C, in the targeted treatment of bladder cancer lymphatic metastasis, belonging to the field of biomedicine technology. The present invention uses the circRNA encoding product that drives bladder cancer lymphatic metastasis as the starting point, screens out circRNA-circSEMA3C that is upregulated in bladder cancer tissue through high-throughput sequencing, and confirms that SEMA3C-123aa, encoded by circSEMA3C, is positively correlated with the occurrence of bladder cancer lymphatic metastasis and can promote bladder cancer lymphangiogenesis and lymphatic metastasis, thereby revealing the biological role of SEMA3C-123aa in bladder cancer lymphatic metastasis and providing a theoretical basis and scientific basis for SEMA3C-123aa as an early diagnostic marker and new treatment target for bladder cancer lymphatic metastasis.